Cargando…

Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials

OBJECTIVES: To evaluate the risk of psychiatric disorders and all-cause mortality associated with belimumab therapy in patients with SLE. METHODS: A literature search of four electronic bibliographic databases, including PubMed, EMBASE, Scopus and Cochrane databases, was conducted for randomised con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Wenhui, Huang, Hong, Zhan, Siyan, Zhang, Zhuoli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547509/ https://www.ncbi.nlm.nih.gov/pubmed/34697129 http://dx.doi.org/10.1136/lupus-2021-000534

Ejemplares similares

Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis
por: Ji, Lanlan, et al.
Publicado: (2022)

Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus
por: Lokhandwala, Tasneem, et al.
Publicado: (2021)

Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA
por: Bell, Christopher F, et al.
Publicado: (2020)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
por: Furie, Richard, et al.
Publicado: (2014)

Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus
por: Jallouli, M, et al.
Publicado: (2014)

Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus Registry
por: Plantinga, Laura C, et al.
Publicado: (2016)

Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study
por: Hao, Yanjie, et al.
Publicado: (2022)

Coping with systemic lupus erythematosus in patients’ words
por: Cornet, Alain, et al.
Publicado: (2022)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
por: Meyer, Aurore, et al.
Publicado: (2020)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
por: Strand, Vibeke, et al.
Publicado: (2020)

Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus
por: Carli, L, et al.
Publicado: (2016)

Complement levels and risk of organ involvement in patients with systemic lupus erythematosus
por: Gandino, Ignacio Javier, et al.
Publicado: (2017)

Serum uric acid is associated with damage in patients with systemic lupus erythematosus
por: Elera-Fitzcarrald, Claudia, et al.
Publicado: (2020)

Living with systemic lupus erythematosus in 2020: a European patient survey
por: Cornet, Alain, et al.
Publicado: (2021)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus
por: Zhu, Lisa, et al.
Publicado: (2022)

Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort
por: Al Sawah, Sarah, et al.
Publicado: (2015)

Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s
por: Albrecht, Katinka, et al.
Publicado: (2014)

Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival
por: Kazzaz, Nayef M, et al.
Publicado: (2015)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
por: Schlencker, Aurelien, et al.
Publicado: (2022)

Association of age with health-related quality of life in a cohort of patients with systemic lupus erythematosus: the Georgians Organized Against Lupus study
por: Plantinga, Laura, et al.
Publicado: (2016)

Perceptions of racism in healthcare among patients with systemic lupus erythematosus: a cross-sectional study
por: Vina, Ernest R, et al.
Publicado: (2015)

Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus
por: Utset, Tammy O, et al.
Publicado: (2015)

Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus
por: Kheir, Joseph M, et al.
Publicado: (2018)

Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy
por: Robinson, Angela Byun, et al.
Publicado: (2014)

Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study
por: Raymond, Warren David, et al.
Publicado: (2021)

Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis
por: Birt, Julie A, et al.
Publicado: (2020)

Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners
por: Arat, Seher, et al.
Publicado: (2017)

Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus
por: Vázquez-Otero, Ileana, et al.
Publicado: (2020)

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
por: Koelmeyer, Rachel, et al.
Publicado: (2020)

Use of a screening questionnaire for systemic lupus erythematosus among pregnant women in a Mexican population
por: Lucero-Morales, Luis, et al.
Publicado: (2021)

Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study
por: Su, Kaisheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lgb2a10n13djsb3nearnkc3v5u